Delivery Order SPE2DB20D2104-SPE2DB24FU95R

Award Date 7/1/24
Potential Completion Date 7/2/24
Potential Value $5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA), a defense agency of the U.S. government. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, and has a ceiling value of $6,794.48. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is September 9, 2024. The contract was not set aside for any specific business type. AmerisourceBergen...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA), a defense agency of the U.S. government. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company, on July 15, 2024 with a ceiling value of $12,983.48 and a completion date of July 16, 2024. This is a firm fixed price delivery order contract, and there is no set-aside designation noted. Amerisourcebergen holds a large Indefinite...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, in the amount of $14,263.98. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of October 18, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA). The $5,773.01 firm fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of October 11, 2024 and was awarded on October 10, 2024. This is a delivery order contract without any set-aside requirements, indicating open competition. AmerisourceBergen holds...
This federal contract award is for the delivery of GARDASIL 9 SYRINGE 0.5ML to the Defense Logistics Agency (DLA), a defense agency. The $10,009.41 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on February 7, 2025, with a final completion date of February 10, 2025. The contract is not designated as a set-aside. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor that plays a critical role in supplying medical products to federal government agencies. The contract, valued at $15,773.30, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and...
This federal contract award is for the delivery of GARDASIL 9 vaccine syringes (0.5mL) to the Defense Logistics Agency (DLA). The $8,433.22 fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an ultimate completion date of January 9, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award is for the delivery of GARDASIL 9 syringes, 0.5 milliliters, to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $24,577.44 and runs through January 10, 2024. It is a firm fixed price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a $999,999,999...
This federal contract award is for the delivery of GARDASIL 9 vaccine syringes to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, on December 27, 2024, with a ceiling value of $8,362.00 and a completion date of December 30, 2024. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical,...
This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 mL) to the Defense Logistics Agency (DLA). The award, valued at $3,898.37, was made on February 28, 2025 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, with a period of performance through March 3, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB24FU95R
    Delivery Order

This federal contract award is for the delivery of GARDASIL 9 syringes (0.5 ml) to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, in July 2024. The contract has a fixed-price delivery order type with a total ceiling value of $4,990.54 and a period of performance through July 2024.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support Medical division, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This award is likely part of that larger IDC, which covers critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic areas. The contract does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 9:47 AM